WestVac BioPharma Co., Ltd.: Significant Progress Made on the Trivalent Recombinant Protein COVID-19 Vaccine against Subvariants including XBB.1.5 and BA.5 by WestVac Biopharma
CHENGDU, China, Feb. 20, 2023 /PRNewswire/ -- Recently, with the support of the National Key R&D Program of China, following the clinical trial approval for Recombinant Variant COVID-19 Vaccine
Dennis Riedl Westvac Biopharma Westvac Biopharma Co Ltd Knowledge City Of Guangzhou Economic Development Zone Innovative Vaccine Production National Key Rd Program Of China
Source: finanznachrichten.de